In the BioHarmony Drug Report Database

"Preview" Icon

Pimavanserin

Nuplazid (pimavanserin) is a small molecule pharmaceutical. Pimavanserin was first approved as Nuplazid on 2016-04-29. It is used to treat hallucinations, parkinson disease, and schizophrenia spectrum and other psychotic disorders in the USA. The pharmaceutical is active against 5-hydroxytryptamine receptor 2A. Nuplazid’s patents are valid until 2038-08-27 (FDA).

 

Trade Name

 

Nuplazid
 

Common Name

 

pimavanserin
 

ChEMBL ID

 

CHEMBL2111101
 

Indication

 

hallucinations, parkinson disease, schizophrenia spectrum and other psychotic disorders
 

Drug Class

 

Serotonin 5-HT2 receptor antagonists

Image (chem structure or protein)

Pimavanserin structure rendering